J Clin Invest. 2019 May 1;129(5):1895-1909. doi: 10.1172/JCI124590. Epub 2019 Feb 26.
Bone osteogenic sarcoma has a poor prognosis as the exact cell of origin and the signaling pathways underling tumor formation remain undefined. Here, we report an osteogenic tumor mouse model based on the conditional knockout of liver kinase b1 (Lkb1; also known as Stk11) in Cathepsin K (Ctsk)-Cre expressing cells. Lineage tracing studies demonstrated that Ctsk-Cre could label a population of periosteal cells. The cells functioned as mesenchymal progenitors with regard to markers and functional properties. LKB1 deficiency increased proliferation and osteoblast differentiation of Ctsk+ periosteal cells, while downregulation of mTORC1 activity, using Raptor genetic mouse model or mTORC1 inhibitor treatment, ameliorated tumor progression of Ctsk-Cre Lkb1fllfl mice. Xenograft mouse models, using human osteosarcoma cell lines, also demonstrated that LKB1 deficiency promoted tumor formation, while mTOR inhibition suppressed xenograft tumor growth. In summary, we identified periosteum-derived Ctsk-Cre expressing cells as a cell of origin for osteogenic tumor and suggested the LKB1-mTORC1 pathway as a promising target for treatment of osteogenic tumor.
骨骨肉瘤的预后较差,因为其确切的起始细胞和肿瘤形成的信号通路仍未确定。在这里,我们报告了一个基于组织蛋白酶 K(Ctsk)-Cre 表达细胞中肝激酶 b1(Lkb1;也称为 Stk11)条件性敲除的成骨肿瘤小鼠模型。谱系追踪研究表明,Ctsk-Cre 可以标记一群骨膜细胞。这些细胞在标记物和功能特性方面具有间充质祖细胞的功能。LKB1 缺失增加了 Ctsk+骨膜细胞的增殖和成骨细胞分化,而使用 Raptor 基因敲除小鼠模型或 mTORC1 抑制剂治疗下调 mTORC1 活性则可改善 Ctsk-Cre Lkb1fllfl 小鼠的肿瘤进展。用人骨肉瘤细胞系进行的异种移植小鼠模型也表明,LKB1 缺失促进了肿瘤的形成,而 mTOR 抑制则抑制了异种移植肿瘤的生长。总之,我们确定了骨膜来源的 Ctsk-Cre 表达细胞为成骨肿瘤的起始细胞,并提出 LKB1-mTORC1 通路是治疗成骨肿瘤的有前途的靶点。